193 related articles for article (PubMed ID: 35896965)
21. Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection.
Al-Obaidi MM; Gungor AB; Nematollahi S; Zangeneh TT; Bedrick EJ; Johnson KM; Low-Adegbija NE; Alam R; Rangan P; William Heise C; Ariyamuthu VK; Shetty A; Qannus AA; Murugapandian S; Ayvaci MMS; Anand PM; Tanriover B
Open Forum Infect Dis; 2022 Jul; 9(7):ofac186. PubMed ID: 35791354
[TBL] [Abstract][Full Text] [Related]
22. The comparative effectiveness of COVID-19 monoclonal antibodies: A learning health system randomized clinical trial.
McCreary EK; Bariola JR; Minnier TE; Wadas RJ; Shovel JA; Albin D; Marroquin OC; Kip KE; Collins K; Schmidhofer M; Wisniewski MK; Nace DA; Sullivan C; Axe M; Meyers R; Weissman A; Garrard W; Peck-Palmer OM; Wells A; Bart RD; Yang A; Berry LR; Berry S; Crawford AM; McGlothlin A; Khadem T; Linstrum K; Montgomery SK; Ricketts D; Kennedy JN; Pidro CJ; Haidar G; Snyder GM; McVerry BJ; Yealy DM; Angus DC; Nakayama A; Zapf RL; Kip PL; Seymour CW; Huang DT
Contemp Clin Trials; 2022 Aug; 119():106822. PubMed ID: 35697146
[TBL] [Abstract][Full Text] [Related]
23. Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals.
Jung J; Kim JY; Park H; Park S; Lim JS; Lim SY; Bae S; Lim YJ; Kim EO; Kim J; Park MS; Kim SH
JAMA Netw Open; 2022 May; 5(5):e2213606. PubMed ID: 35608859
[TBL] [Abstract][Full Text] [Related]
24. Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US.
Flaxman AD; Issema R; Barnabas RV; Ross JM
JAMA Netw Open; 2022 Apr; 5(4):e228632. PubMed ID: 35452104
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
McCreary EK; Lemon L; Megli C; Oakes A; Seymour CW;
Ann Intern Med; 2022 Dec; 175(12):1707-1715. PubMed ID: 36375150
[TBL] [Abstract][Full Text] [Related]
26. SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.
Griffin JB; Haddix M; Danza P; Fisher R; Koo TH; Traub E; Gounder P; Jarashow C; Balter S
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1170-1176. PubMed ID: 34437525
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients.
Sarrell BA; Bloch K; El Chediak A; Kumm K; Tracy K; Forbes RC; Langone A; Thomas L; Schlendorf K; Trindade AJ; Perri R; Wright P; Concepcion BP
Transpl Infect Dis; 2022 Feb; 24(1):e13759. PubMed ID: 34787345
[TBL] [Abstract][Full Text] [Related]
28. Transmission of and Infection With COVID-19 Among Vaccinated and Unvaccinated Attendees of an Indoor Wedding Reception in Minnesota.
Wienkes H; Vilen K; Lorentz A; Gerlach D; Wang X; Saupe A; Danila R; Lynfield R; Smith K; Medus C
JAMA Netw Open; 2022 Feb; 5(2):e220536. PubMed ID: 35212747
[TBL] [Abstract][Full Text] [Related]
29. Retrospective Analysis of Vaccinated and Unvaccinated COVID-19 Patients Treated with Monoclonal Antibodies (mAb) and Their Emergent Needs (RAVEN).
Simeunovic G; Polega J; Toor S; Andersen NJ
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992272
[TBL] [Abstract][Full Text] [Related]
30. Mortality and risk factors of vaccinated and unvaccinated frail patients with COVID-19 treated with anti-SARS-CoV-2 monoclonal antibodies: A real-world study.
Nevola R; Feola G; Ruocco R; Russo A; Villani A; Fusco R; De Pascalis S; Core MD; Cirigliano G; Pisaturo M; Loffredo G; Rinaldi L; Marrone A; Starace M; Sposito PL; Cozzolino D; Salvatore T; Lettieri M; Marfella R; Sasso FC; Coppola N; Adinolfi LE
Int J Infect Dis; 2023 Jun; 131():155-161. PubMed ID: 36944382
[TBL] [Abstract][Full Text] [Related]
31. Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
Ganesh R; Philpot LM; Bierle DM; Anderson RJ; Arndt LL; Arndt RF; Culbertson TL; Destro Borgen MJ; Hanson SN; Kennedy BD; Kottke BB; Larsen JJ; Ramar P; Rosedahl JK; Seville MT; Speicher LL; Tulledge-Scheitel SM; Wilker CG; Razonable RR
J Infect Dis; 2021 Oct; 224(8):1278-1286. PubMed ID: 34279629
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
[TBL] [Abstract][Full Text] [Related]
33. A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients.
Ahearn AJ; Thin Maw T; Mehta R; Emamaullee J; Kim J; Blodget E; Kahn J; Sher L; Genyk Y
Transplantation; 2022 Feb; 106(2):e153-e157. PubMed ID: 34519680
[TBL] [Abstract][Full Text] [Related]
34. Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: A single-center, propensity-matched cohort study.
Rhudy C; Bochenek S; Thomas J; St James G; Zeltner M; Platt T
Am J Health Syst Pharm; 2023 Jan; 80(3):130-136. PubMed ID: 36264659
[TBL] [Abstract][Full Text] [Related]
35. Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria.
Schiaroli E; De Socio GV; Gidari A; Malincarne L; Benedetti S; Lanzi A; Bastianelli S; Pierucci S; Busti C; Fagotti B; Vicenti I; Zazzi M; Francisci D
Mediterr J Hematol Infect Dis; 2022; 14(1):e2022050. PubMed ID: 35865399
[TBL] [Abstract][Full Text] [Related]
36. Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study.
Cooper MH; Christensen PA; Salazar E; Perez KK; Graviss EA; Nguyen D; Musser JM; Huang HJ; Liebl MG
Open Forum Infect Dis; 2021 Nov; 8(11):ofab512. PubMed ID: 35559124
[TBL] [Abstract][Full Text] [Related]
37. Imaging Severity COVID-19 Assessment in Vaccinated and Unvaccinated Patients: Comparison of the Different Variants in a High Volume Italian Reference Center.
Granata V; Fusco R; Villanacci A; Magliocchetti S; Urraro F; Tetaj N; Marchioni L; Albarello F; Campioni P; Cristofaro M; Di Stefano F; Fusco N; Petrone A; Schininà V; Grassi F; Girardi E; Ianniello S
J Pers Med; 2022 Jun; 12(6):. PubMed ID: 35743740
[TBL] [Abstract][Full Text] [Related]
38. Experience of the United Arab Emirates in the use of monoclonal antibody drug sotrovimab in high-risk vaccinated and unvaccinated patients with COVID-19: an observational cohort study.
Abdalateef S; Al Meheiri NM; Nassef M; Shorrab AA; Hashimi OAR; Allam S; Alnaqbi MS; Al-Rifai RH
BMJ Open; 2023 Jan; 13(1):e066095. PubMed ID: 36627160
[TBL] [Abstract][Full Text] [Related]
39. Spike-specific T-cell responses in patients with COVID-19 successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2.
Rotundo S; Vecchio E; Abatino A; Giordano C; Mancuso S; Tassone MT; Costa C; Russo A; Trecarichi EM; Cuda G; Costanzo FS; Palmieri C; Torti C
Int J Infect Dis; 2022 Nov; 124():55-64. PubMed ID: 36116671
[TBL] [Abstract][Full Text] [Related]
40. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
Wynia MK; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele JD; Stocker HR; Wogu AF; Zane RD; Sokol RJ; Ginde AA
Chest; 2023 May; 163(5):1061-1070. PubMed ID: 36441040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
